Thermo Fisher Scientific TMO Payments for Repurchase of Common Stock

Payments for Repurchase of Common Stock at other companies

Bio-Rad LaboratoriesBIO

——

RevvityRVTY

——

IlluminaILMN

——

IQVIAIQV

——

Other financials

Income statement

See full

Revenue$12.0B—

Operating income$2.1B—

Net income$1.7B+7.4%

EPS (diluted)$4.68+9.3%

Balance sheet

See full

Cash & equivalents$4.1B-11.7%

Total debt$39.2B+4.6%

Total equity$52.7B+4.3%

Total assets$113.17B+11.8%

Cash flow

See full

Operating cash flow$2.1B+51.9%

CapEx-$1.2B-509%

Free cash flow$923.0M-16.5%

Valuation

See full

Market cap$214.21B+17.7%

Enterprise value$249.32B+16.0%

P/E30.8×+3.1×

P/S4.8×-0.9×

Profitability

See full

Gross margin58.3%—

Operating margin17.2%+0.8pp

Net margin15.2%+1.0pp

FCF margin15.7%-2.1pp

Returns & leverage

See full

Return on equity13.5%+0.1pp

Debt / equity0.7×0.0×

Current ratio1.6×-0.4×

Where this comes from

Reported directly by Thermo Fisher Scientific in its filing.

Tagged under the XBRL concept us-gaap:PaymentsForRepurchaseOfCommonStock.

The official record: Thermo Fisher Scientific’s 8-K, filed July 23, 2026, on SEC EDGAR. View the filing →

Ask your AI about Thermo Fisher Scientific's payments for repurchase of common stock.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Thermo Fisher Scientific's payments for repurchase of common stock?: Thermo Fisher Scientific (TMO) reported payments for repurchase of common stock of -$7B in Q2 2026.